Research We Funded
Your generous support enables ALS United Orange County to fund global research every year, in locations across the globe. From individual projects to global collaborations, we provide funding to experts in a variety of scientific focus areas critical to advancing the search for treatments and a cure for ALS.
Accelerating Medicines Partnership for ALS (AMP® ALS)
ALS United® is proud to support the Accelerating Medicines Partnership® in Amyotrophic Lateral Sclerosis (AMP® ALS) with a commitment of $500,000 from our members. This initiative is a collaborative effort involving the National Institutes of Health (NIH), the Foundation for the National Institutes of Health (FNIH), the Food and Drug Administration (FDA), pharmaceutical and biotechnology companies, and non-profit organizations. AMP ALS is designed to accelerate the identification of new and effective therapies for people living with amyotrophic lateral sclerosis (ALS) or at risk for developing the disease.
AMP ALS addresses the challenges of disease heterogeneity, fragmented research efforts, decentralized data storage, and a lack of standardized clinical tools. Through this public-private partnership, the development of new diagnostics and treatments is being transformed by jointly identifying and validating promising biomarkers, new and optimized clinical outcome assessments, and biological targets for therapeutics.
Research We Funded
ALS United® members demonstrate an unwavering commitment to advancing ALS research through substantial and diverse funding initiatives. For the current fiscal year (February 1, 2024 – January 31, 2025), our members have already committed nearly $3 million dollars to a robust research portfolio.
This includes funding for:
- AMP ALS (FNIH)
- ALS Research Network
- ALS Research Fellowships
- Northeast ALS Consortium
- American Brain Foundation ALS Research
- Essey Research Award
This diverse portfolio reflects our members’ dedication to exploring multiple avenues in the fight against ALS, from basic science to clinical trials and innovative therapies. These figures represent only a portion of our members’ total research investment, as they do not include millions of dollars in commitments to active research initiatives from previous fiscal years.